Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALT001 in Osteoarthritis
NCT07404891Active, not recruiting
- Start
- Mar 2026
- Primary completion
- Sep 2026
- Modality
- Small Molecules, Stem Cell Therapies
- Countries
- 1
01
Overview
Randomised, double-blind trial of ALT001 in osteoarthritis (OA). Primary endpoints: WOMAC Pain Score at 24 weeks and Levels of inflammatory factors IL-1β, IL-6, and TNF-α in synovial fluid. Started Mar 2026; status: active, not recruiting.
02
Drugs
ALT001
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT07404891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07404891.